Mill Capital Management LLC Acquires 237 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 3rd, 2023

Mill Capital Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 111,629 shares of the company’s stock after acquiring an additional 237 shares during the quarter. Johnson & Johnson makes up approximately 2.2% of Mill Capital Management LLC’s holdings, making the stock its 13th biggest position. Mill Capital Management LLC’s holdings in Johnson & Johnson were worth $19,719,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at $35,000. Retirement Financial Solutions LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at $40,000. TD Capital Management LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $48,000. Iron Horse Wealth Management LLC grew its stake in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after buying an additional 159 shares in the last quarter. Finally, Piershale Financial Group Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at $61,000. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 1.0 %

JNJ opened at $155.00 on Monday. The company has a market capitalization of $403.66 billion, a P/E ratio of 23.00, a P/E/G ratio of 2.64 and a beta of 0.54. The stock has a fifty day moving average of $158.02 and a 200-day moving average of $167.18. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.13 earnings per share. On average, equities analysts expect that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price for the company. Atlantic Securities lifted their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Piper Sandler reduced their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, Citigroup lifted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.67.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.